080210xf's Blog

L'X fragile sera vaincu | Fragile X will be conquered

Results of first clinical trial of minocycline in Fragile X are very promising!

October 12, 2010 |

Results of the first clinical trial of minocycline in Fragile X patients were published today in BMC Neurology, and they suggest that this medication can improve challenging behaviors commonly seen in Fragile X syndrome.

Open-label add-on treatment trial of minocycline in fragile X syndrome
BMC Neurology 2010, 10:91 Carlo Paribello, Leeping Tao, Anthony Folino, Eizabeth Berry-Kravis, Michael Tranfaglia, Iryna M Ethell, Douglas W Ethell

Twenty males and females with Fragile X, ages 13-32, participated in this open-label add-on trial at the Fragile X clinic in Toronto, Canada. Dr. Carlo Paribello, himself father of two boys with Fragile X, led the trial which was funded by FRAXA. Patients received either 100 mg or 200 mg of minocycline daily, and their behaviors were evaluated prior to treatment and again 8 weeks after daily minocycline.

Behavioral scores showed striking improvement and the drug was generally well tolerated. The most significant side effect noted was, in blood tests, an asymptomatic seroconversion to a positive ANA in two people. This is a nonspecific marker of immunoinflammatory connective tissue diseases, so physicians who prescribe minocycline should be aware of its risk for inducing potentially serious autoimmune phenomena.

Fraxa

No comments yet»

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: